Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors

Recent clinical development of KRAS inhibitors has heightened interest in the genomic landscape of KRAS-altered cancers. We performed a pan-cancer analysis of KRAS-altered samples from 426,706 adult patients with solid or hematologic malignancies using comprehensive genomic profiling; additional ana...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Jessica K., Sivakumar, Smruthy, Schrock, Alexa B., Madison, Russell, Fabrizio, David, Gjoerup, Ole, Ross, Jeffrey S., Frampton, Garrett M., Napalkov, Pavel, Montesion, Meagan, Schutzman, Jennifer L., Ye, Xin, Hegde, Priti S., Nagasaka, Misako, Oxnard, Geoffrey R., Sokol, Ethan S., Ou, Sai-Hong Ignatius, Shi, Zhen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9734185/
https://www.ncbi.nlm.nih.gov/pubmed/36494601
http://dx.doi.org/10.1038/s41698-022-00334-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9734185/
https://www.ncbi.nlm.nih.gov/pubmed/36494601
http://dx.doi.org/10.1038/s41698-022-00334-z

Ejemplares similares